Abstract
It is well established that cancer increases the risk of venous thrombosis. Conversely, the mechanisms involved in haemostasis play a major role in the tumour development, facilitating tumour proliferation and altering the microenvironment, with major consequences in terms of the metastatic process. It is therefore mandatory to take the measure of this double bond between cancer and haemostasis. The clinicianwill be aware that venous thromboembolism is difficult to diagnose in cancer patients. At all stages of care, preventive and curativemeasures will be implemented, based on current recommendations and, if applicable, the standards which have been developed. With the French Group Thrombosis and Cancer (GFTC), a dynamics has been boosted in order to implement “RCP-thrombose”.
Résumé
Le cancer est une maladie favorisant la thrombose veineuse. Réciproquement, des mécanismes impliqués dans l’hémostase jouent un rôle déterminant dans le développement de la tumeur, en facilitant la prolifération tumorale et en modifiant le microenvironnement, ce qui peut avoir des conséquences sur le processus métastatique. Prendre la mesure de ce double lien apparaît aujourd’hui comme une nécessité. Le clinicien sera donc sensibilisé afin de ne pas méconnaître un diagnostic de maladie thromboembolique veineuse. À toutes les étapes de la prise en charge du patient atteint de cancer, lesmesures préventives et curatives seront mises en place, s’appuyant sur les recommandations en vigueur et, le cas échéant, sur les référentiels qui auront été élaborés. Avec le Groupe français thrombose et cancer (GFTC), une dynamique est insufflée en France pour que de véritables RCP thromboses soient mises en place.
Similar content being viewed by others
Références
Ay C, Dunkler D, Marosi C, et al (2010) Prediction of venous thromboembolism in cancer patients. Blood 116: 5377–5382
Bambace NM, Holmes CE (2011) The platelet contribution to cancer progression. J Thromb Haemost 9: 237–249
Chand HS, Ness SA, Kisiel W (2006) Identification of a novel human tissue factor splice variant that is upregulated in tumor cells. J Cancer 118: 1713–1720
Heit JA, O’Fallon WM, Petterson TM, et al (2002) Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 162: 1245–1248.
Hoekstra J, Leebeek FW, Plessier A, et al (2009) Paroxysmal nocturnal hemoglobinuria in Budd-Chiari syndrome: findings from a cohort study. J Hepatol 5: 696–706
Je Y, Schutz FA, Choueiri TK (2009) Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol 10: 967–974
Khorana AA, Kuderer NM, Culakova E, et al (2008) Development and validation of a predictive model for chemotherapy associated thrombosis. Blood 111: 4902–4907
Kiladjan JJ, Cervantes F, Leebeck FW, et al (2008) The impact of JAK-2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood 15: 4922–4929
Kuderer NM, Khorana AA, Lyman GH, et al (2007) A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer 110: 1149–1161
Laporte S, Mismetti P, Decousus H, et al (2008) Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de le Enfermenddad ThromboEmbolica venosa (RIETE) Registry. Circulation 117: 1711–1716
Lazo-Langner A, Goss GD, Spaans JN, et al (2007) The effect of low-molecular weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials. J Thromb Haemost 5: 729–737
Liu Y, Jiang P, Capkova K, et al (2011) Tissue factor-activated coagulation cascade in the tumor microenvironment is critical for tumor progression and an effective target for therapy. Cancer Res 71: 899–910
Palumbo A, Rajkumar SV, Dimopoulos MA, et al (2008) Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22: 414–423
Palumbo JS, Talmage KE, Massari JV, et al (2005) Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 105: 178–185
Rak J (2010) Microparticles in cancer. Semin Thromb Haemost 36: 888–906
Rak J, Klement G (2000) Impact of oncogenes and tumor suppressor genes on deregulation of haemostasis and angiogenesis in cancer. Cancer Metastasis Rev 19: 93–96
Rickles FR (2006) Mechanisms of cancerinduced thrombosis in cancer. Pathophysiol Haemost Thromb 35: 103–110
Saphner T, Tormey DC, Gray R (1991) Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 9: 286–294
Starling N, Rao S, Cunningham D, et al (2009) Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group. J Clin Oncol 27: 3786–3793
Van Sluis GL, Brüggeman LW, Esmon CT, et al (2011) Endogenous activated protein C is essential for immune-mediated cancer cell elimination from the circulation. Cancer Lett 306: 106–110
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Nguyen, P. Synthèse et conclusion. Oncologie 14, 667–670 (2012). https://doi.org/10.1007/s10269-012-2234-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10269-012-2234-x